March 13 Deadline Alert: Law Offices of Howard G. Smith Reminds Seattle Genetics, Inc. Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm

BENSALEM, Pa.--()--Law Offices of Howard G. Smith reminds investors of the upcoming March 13, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of a class of investors who purchased or otherwise acquired Seattle Genetics, Inc. (“Seattle Genetics” or the “Company”) (NASDAQ: SGEN) securities between October 27, 2016 and December 23, 2016, inclusive (the “Class Period”). Seattle Genetics investors have until March 13, 2017 to file a lead plaintiff motion.

Seattle Genetics is a biotechnology company that develops and commercializes targeted therapies for the treatment of cancer.

On December 27, 2016, Seattle Genetics disclosed that the U.S. Food and Drug Administration (“FDA”) had placed a clinical hold or partial clinical hold on the Company's experimental cancer drug, vadastuximab talirine. The purpose of the hold, according to the FDA, was to evaluate the risk of hepatotoxicity. Seattle Genetics stated that six acute myeloid leukemia patients had been identified with liver toxicity and that four had died. On this news, shares of Seattle Genetics fell over 16% on December 27, 2016.

The Complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) vadastuximab talirine presents a significant risk of fatal hepatotoxicity; (ii) as such, Seattle Genetics had overstated the viability of vadastuximab talirine as an AML treatment; and (iii) as a result of the foregoing, Seattle Genetics' public statements were materially false and misleading at all relevant times.

If you purchased Seattle Genetics shares, you may move the Court no later than March 13, 2017 to request appointment as lead plaintiff. To be a member of the class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Release Summary

March 13 Deadline Alert: Law Offices of Howard G. Smith Reminds Seattle Genetics, Inc. Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com